Results 181 to 190 of about 23,380,862 (254)

Anodal Transcranial Direct Current Stimulation Improves Social Behavior Alongside Neuroplastic Changes in a Tsc2+/− Rat Model of Autism Spectrum Disorder

Autism Research, EarlyView.
ABSTRACT Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by altered synaptic connectivity and network organization, resulting in profound impairments in social communication and interaction. Transcranial direct current stimulation (tDCS) represents a promising approach to modulate maladaptive plasticity associated with ASD;
Antonia Ramme, Rebecca Winter, Natalia Jarzebska, Fatih Ögel, Marten Julian Richter, Iveta Vojtechova, Christine Winter, Tomas Petrasek, Robert Waltereit, Nadine Bernhardt   +9 more
wiley   +1 more source

Recent Non‐Suicidal Self‐Injury in Autistic Adolescents and Adults: Characteristics, Clinical Correlates and Suicidal Thoughts and Behaviors

Autism Research, EarlyView.
ABSTRACT Non‐suicidal self‐injury (NSSI) is prevalent among autistic adolescents and adults, yet research on its clinical characteristics, functions, and association with suicidal thoughts and behaviors (STBs) in this population remains limited. This study compared these domains between autistic adolescents and adults with and without recent NSSI.
Safaa Eldeeb, Ligia Antezana, Caitlin M. Conner, Kelly B. Beck, Sarah E. Victor, Aliona Tsypes, Lori N. Scott, Carla A. Mazefsky   +7 more
wiley   +1 more source

A scoping review of thresholds for responder and time‐to‐event analysis of patient‐reported outcomes in breast cancer trials

British Journal of Clinical Pharmacology, EarlyView.
Patient‐reported outcomes (PROs) are essential for assessing clinical benefit and tolerability from the patient's perspective. In oncology trials, PRO data analysis often involves responder and time‐to‐event analyses, which depend on predefined thresholds to determine clinically meaningful change.
Anna Margarete Maria Thurner, Daniela Krepper, Micha Johannes Pilz, Lisa Marie Storz, Maike Thumfart, Johannes Maria Giesinger   +5 more
wiley   +1 more source

Zuranolone: A case study in (regulatory) rush to judgement?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove, Milutin Kostic, Barbara Mintzes, Gianna D'Ambrozio, Allen Shaughnessy   +4 more
wiley   +1 more source

Exploring new avenues: Psychedelic‐assisted therapy for young people

British Journal of Clinical Pharmacology, EarlyView.
Rates of mental illness in young people are increasing, whereas the development of novel mental health treatments has not significantly progressed. Psychedelic‐assisted therapy, using substances such as psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA), has shown potential in the treatment of mental illnesses in the adult population, including ...
Ioanna Artemis Vamvakopoulou, Dasha Nicholls, David J. Nutt, Martina Di Simplicio   +3 more
wiley   +1 more source